Bevacizumab 'Not Cost-effective for Glioblastoma'Bevacizumab 'Not Cost-effective for Glioblastoma'

The drug is not cost-effective as a first-line treatment for glioblastoma and does not merit further investigation, say Canadian researchers. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news